SCHEDULE 13G/A: Orca Capital AG Discloses 4.9% Stake in Enveric Biosciences, Files Amended Schedule 13G

Orca Capital AG has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Enveric Biosciences, Inc. as of January 31, 2025.

Summary

• Orca Capital AG, a German entity, has filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Enveric Biosciences, Inc.
• As of January 31, 2025, Orca Capital AG beneficially owns 97,019 shares of Enveric Biosciences, Inc. Common Stock.
• This ownership represents 4.9% of the outstanding class of securities.
• Orca Capital AG holds sole voting power and sole dispositive power over all 97,019 shares.
• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
• The reported ownership excludes shares issuable upon the exercise of certain warrants containing blocker provisions, which prevent beneficial ownership from exceeding 4.99%. Specifically, 310,963 shares from warrants are excluded due to this provision.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It neither indicates positive nor negative operational performance, but rather a standard investment position.

Positives

• Orca Capital AG's investment indicates a level of confidence in Enveric Biosciences, Inc.
• The filing clarifies the ownership structure, providing transparency to the market regarding a significant shareholder.

Negatives

• The blocker provision on warrants limits Orca Capital AG's ability to increase its stake beyond 4.99% through warrant exercise, potentially capping its influence or future investment via this mechanism.

Risks

• The existence of blocker provisions on warrants means that Orca Capital AG cannot increase its beneficial ownership above 4.99% through the exercise of 310,963 shares from warrants, which could limit potential future investment or strategic flexibility for the reporting person.

Future Outlook

N/A. This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of a significant ownership stake by an investment entity in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends but reflects an investment decision within the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant investor's stake and their stated intent (not to influence control).
• Company Management: Awareness of a significant, passive investor in the company's stock.

Key Dates

Keywords

Enveric Biosciences, Orca Capital AG, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholder, Biotechnology, Pharmaceuticals